Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Polaris Group.

    Client Virtual Booth

    POLARIS GROUP

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Polaris Group
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10675 Sorrento Valley Rd. Suite 200, San Diego, CA 92121
    Telephone
    Telephone
    +1-858-4526688
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://polarispharma.com/contact-us/?lang=en
    Linkedin
    Linkedin
    https://www.linkedin.com/company/polaris-pharmaceuticals/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Le...

    Details:

    ADI-PEG 20 (pegargiminase) is an Arginine Degrader Enzyme drug candidate, which is currently being evaluating clinical trial studies with patients for the treatment of Leiomyosarcoma.


    Lead Product(s): Pegargiminase,Gemcitabine,Docetaxel

    Therapeutic Area: Oncology Product Name: ADI-PEG 20

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 04, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study

    Details:

    ADI-PEG 20 (pegylated arginine deiminase, pegargiminase) is designed to deplete the external supply of arginine, and is being investigated for Non-Alcoholic Steatohepatitis (NASH).


    Lead Product(s): Pegargiminase

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ADI-PEG 20

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 29, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma

    Details:

    ADI-PEG 20 (pegargiminase) ia arginie degrader, which is being evaluated in phase 2/3 clinical trials in combination with cisplatin & pemetrexed for the treatment of malignant pleural mesothelioma.


    Lead Product(s): Pegargiminase,Cisplatin,Pemetrexed

    Therapeutic Area: Oncology Product Name: ADI-PEG 20

    Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 16, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Global Coalition for Adaptive Research and Polaris Group Announce Commencement of ADI-PEG 20 in GBM AGILE Trial

    Details:

    ADI-PEG 20 (pegargiminase) is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed, which is investigated for glioblastoma.


    Lead Product(s): Pegargiminase

    Therapeutic Area: Oncology Product Name: ADI-PEG 20

    Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule

    Recipient: Global Coalition for Adaptive Research

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 15, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    bora-pharmaceuticals-2024-07-01

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search